臨床眼科72巻11号

2018年10月発行

増刊号 7年前の常識は現在の非常識！—眼科診療の最新標準 4．網膜・硝子体疾患 2）診断・治療

抗VEGF療法

著者： 丸子一朗¹

所属機関： ¹東京女子医科大学眼科学教室

ページ範囲：P.243 - P.249

ここが変わった！

以前の常識

　●AMD：抗VEGF薬のPRN投与

　●mCNV：治療法なし（保険適用外の抗VEGF療法）

　●DME・RVOによる黄斑浮腫：レーザー治療，ステロイド治療，硝子体手術

現在の常識

　●AMD：抗VEGF薬のTAEまたはPRN投与

　●mCNV：保険適用の抗VEGF療法

　●DME・RVOによる黄斑浮腫：抗VEGF療法が第一選択

参考文献

1）Rosenfeld PJ, Brown DM, Heier JS et al：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355：1419-1431, 2006

2）Brown DM, Kaiser PK, Michels M et al：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355：1432-1444, 2006

3）Heier JS, Brown DM, Chong V et al：Intravitreal aflibercept（VEGF trap-eye）in wet age-related macular degeneration. Ophthalmology 119：2537-2548, 2012

4）Lalwani GA, Rosenfeld PJ, Fung AE et al：A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration：year 2 of the PrONTO Study. Am J Ophthalmol 148：43-58, 2009

5）Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration（ALTAIR）. Data presented at the 17th EURETINA Congress 2017, Barcelona, Spain

6）Grunwald JE, Daniel E, Huang J et al：Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121：150-161, 2014

7）Koh A, Lai TYY, Takahashi K et al：Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy：a randomized clinical trial. JAMA Ophthalmol 135：1206-1213, 2017

8）Lee WK, Iida T, Ogura Y et al：Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study：a randomized clinical trial. JAMA Ophthalmol doi：10.1001/jamaophthalmol.2018.1804, 2018

9）Wolf S, Balciuniene VJ, Laganovska G et al：RADIANCE：a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121：682-692, 2014

10）Ikuno Y, Ohno-Matsui K, Wong TY et al：Intravitreal aflibercept injection in patients with myopic choroidal neovascularization：The MYRROR Study. Ophthalmology 122：1220-1227, 2015

11）Brown DM, Campochiaro PA, Bhisitkul RB et al：Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion：12-month outcomes of a phase III study. Ophthalmology 118：1594-1602, 2011

12）Campochiaro PA, Brown DM, Awh CC et al：Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion：twelve-month outcomes of a phase III study. Ophthalmology 118：2041-2049, 2011

13）Clark WL, Boyer DS, Heier JS et al：Intravitreal aflibercept for macular edema following branch retinal vein occlusion：52-week results of the VIBRANT study. Ophthalmology 123：330-336, 2016

14）Brown DM, Heier JS, Clark WL et al：Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion：1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155：429-437, 2013

15）Brown DM, Nguyen QD, Marcus DM et al：Long-term outcomes of ranibizumab therapy for diabetic macular edema：the 36-month results from two phase III trials：RISE and RIDE. Ophthalmology 120：2013-2022, 2013

16）Elman MJ, Aiello LP, Beck RW et al：Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117：1064-1077, 2010

17）Mitchell P, Bandello F, Schmidt-Erfurth U et al：The RESTORE study：ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118：615-625, 2011

18）Ishibashi T, Li X, Koh A et al：The REVEAL Study：ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 122：1402-1415, 2015

19）Korobelnik JF, Do DV, Schmidt-Erfurth U et al：Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121：2247-2254, 2014

20）Wells JA, Glassman AR, Ayala AR et al：Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372：1193-1203, 2015